

## Discovery Biology Solutions



With wide-ranging capabilities in biology, Aragen offers high quality, seamless and cost effective solutions across the Pharma and Biotech value chain. Biological assessment of New Molecular Entities (NMEs) plays a crucial role in ascertaining structure activity relationships, potency, selectivity, druggability and *in vitro* and *in vivo* efficacy evaluation.

Our capabilities include reagent generation, highthroughput screening, assay development, biomarker validation, radiometric assays, DMPK, animal pharmacology (disease models) and exploratory toxicology for small molecules and biologics.

#### In Vitro Pharmacology

#### **Primary Pharmacology**

#### A. Target Class

- Enzymes
- GPCRs
- Transporters
- Ion channels

### B. Assay Platforms & Technologies

- Real Time QPCR (Quantstudio 6 Flex)
- Absorbance / Luminescence / Fluorescence (HRTF/ FP/ TR-FRET)

- Radiometry
- FLIPR-based screening
- Chromatography (TLC/ HPLC/ LCMS / MS)
- HTMS (Rapid Fire System)
- Flow cytometry (BD FACSVerse)
- SPR (Biacore T200)
- Manual Patch Clamp (Axon)
- Automated Western Blotting (WES)
- Multiplexed Detection (MAGPIX)
- Next Gen Sequencing (Ion Torrent S5)

- High Content Screening (Cellinsight Cx7)
- Precision Nanoliter Liquid Handling (ECHO 550)
- High Throughput Screening

#### C. Model Systems

- Cell lines
- Normal primary cells
- Patient-derived primary cells
- Stem cells
- 3D cell culture

#### **Reagent Generation**

- Gene synthesis
- Cloning/sub-cloning
- E.coli expression
- Baculovirus expression
- Yeast expression
- Mammalian (CHO/HEK)
- Lentiviral expression Tagged / Untagged / Radiolabeled protein production

#### **Cosmetics & Personal care**

- Skin care assays
- Hair care assays
- Anti-ageing assays
- Anti-pollution test
- REACH/OECD guided assays
- Bio compatibility testing

#### In Vitro Toxicology

- Genotox (AMES/ Micronucleus etc.)
- Hepato toxicity
- Cardio toxicity

- Dermal toxicity
- Ocular toxicity
- Mitochondrial toxicity
- Neuro toxicity

- Vaginal toxicity
- Toxicogenomic profiling
- Endocrine disruptor screening

#### **DMPK Services**

TARGET TO HIT

HIT TO LEAD

LEAD TO CANDIDATE IDENTIFICATION

CANDIDATE SELECTION

# Assessment of Physiochemical & in vitro ADME Properties

- In Silico properties
- Solubility
- Log D
- Metabolic stability
- CYP inhibition

#### Optimisation of Physiochemical & Druggable Properties

- Metabolic stability
- CYP inhibition
- Permeability
  - PAMPA
  - CACO 2
- Plasma / Tissue protein binding
- Reactive metabolite
- In Vivo PK (rodent)

# Optimisation of Druggable Properties, IVIVC, PK/PD Correlation

- Permeability
  - CACO 2
- Plasma / Tissue protein binding
- Blood / Plasma partitioning
- Met id (soft spot)
- PK (non-rodent)
- PK (rodent)
- Target tissue exposure
- IVIVC, renal / biliary CL
- Mass balance
- PK/PD

#### Dose Range Finding, Safety/Tox Assessment, Interspecies Scaling

- Dose range finding studies (rodents and non-rodents)
- PK/PD
- Tissue distribution
- Food effect
- Gender effect
- Metabolite profiling / Metabolism pathway
- Safety profiling
- Toxicokinetics
- CYP induction
- Interspecies scaling

#### In Vivo Pharmacology

Our animal facility is accredited by **AAALAC** and **CPCSEA** (India) for ethical treatment of animals. All the animal experiments are conducted in accordance with **IAEC** approved protocols.

Aragen's rodent facility is also certified by **OHSAS** for strictly following all recommended rules for health and safety of our employees.

#### **Animal Models of Oncology**

- Xenograft cancer models
- Syngeneic tumor models

### **Animal Models of Metabolic Disorders**

- Obesity
- NASH STELIC
- Diabetes

#### **Animal Models of Pain**

- Neuropathic pain models
- Incisional/Post-operative pain models
- Inflammatory pain models

#### **Animal Models of Inflammation**

- Acute inflammation
- Colon inflammation
- Dermal inflammation
- Neuro inflammation

#### **Animal Models of Fibrosis**

- Pulmonary fibrosis
- Liver fibrosis

#### **Integrated Services**

Ability to provide solutions across chemistry, *in vitro* pharmacology, DMPK, *in vivo* pharmacology and safety

Experience in driving programs from target validation to clinical candidate selection

Project management provided as a resource to handle all non-scientific logistical aspects of an integrated program

Let's begin the conversation

E: bd@aragen.com
W: aragen.com
in /company/aragen-life-sciences
f/AragenLifeSciences



